Every 8-K that AdaptHealth Corp. (AHCO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AHCO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AHCO filings page.
AdaptHealth Corp. (AHCO) announced a planned Chief Financial Officer transition, appointing Harriss Currie as CFO effective September 9, 2026, while current CFO Jason Clemens will cease serving as CFO on September 8, 2026 and remain through October 1, 2026 to assist with the transition.
Currie joins with extensive healthcare and diagnostics experience, including more than 15 years as CFO of Luminex Corp. His employment agreement provides an annual base salary of $670,000 and a target annual bonus equal to 100% of base salary, with a prorated 2026 bonus. As an inducement, he will receive RSUs valued at $818,462, half vesting annually over three years and half cliff-vesting on the third anniversary of his start date, subject to continued employment. Upon certain qualifying terminations, he is eligible for 12 months of base-salary severance, a prorated bonus (under stated conditions), and 12 months of COBRA health coverage, subject to a release and restrictive covenants.
AdaptHealth reported second-quarter 2026 net revenue of $740.3 million, up 12.7% from $657.1 million, with 15.9% organic growth across all segments. A $144.2 million goodwill impairment in the Respiratory Health and Wellness at Home reporting units drove a sharp swing to a net loss attributable to AdaptHealth Corp. of $145.3 million versus net income of $4.2 million a year earlier. Adjusted EBITDA slipped 3.2% to $132.0 million, with margin declining to 17.8% from 20.8%. Year-to-date 2026 cash from operations was $239.0 million versus $257.5 million, and free cash flow turned negative $48.4 million versus $73.3 million in 2025. Registered myAPP users surpassed 512,000, 56% above year-end 2025.
The company agreed to sell its Diabetes Health business for $235.0 million in cash, which will be reported as discontinued operations, and formed an e-commerce joint venture adding home sleep testing. Management completed a workforce restructuring expected to yield $19 million in annualized savings and refinanced, redeeming 6.125% Senior Notes due 2028 using a $325 million delayed-draw term loan. Full-year 2026 guidance on a continuing-operations basis was reset to net revenue of $2.85–$2.89 billion, Adjusted EBITDA of $490–$520 million, and free cash flow of $80–$120 million. Versus prior EBITDA guidance of $680–$730 million, the revision reflects a $100 million impact from classifying Diabetes Health as discontinued operations (including $60 million of overhead that will partly remain), plus $55 million from the West Coast capitated contract, $30 million from a manufacturer price increase, and $15 million from other portfolio actions.
AdaptHealth Corp. agreed on July 19, 2026 to sell substantially all assets of its Diabetes Health business to RGH Enterprises, LLC, a Cardinal Health subsidiary, for $235 million in cash, subject to a net working capital adjustment. The buyer will assume specified liabilities, and will place $8.0 million of the price in escrow for post-closing adjustments and $18.8 million to secure AdaptHealth’s indemnification obligations. Closing conditions include antitrust clearance under the Hart-Scott-Rodino Act and other competition and healthcare laws, absence of legal prohibitions or a material adverse effect on the business, accuracy of representations and covenants, completion of a separation plan, and acceptance of employment offers by at least 80% of offered employees including a key employee.
The agreement includes a four-year non-compete in North America, a two-year non-solicitation covenant for transferred personnel, and a seven-year confidentiality obligation. It can be terminated for customary reasons, including failure to close within 12 months; in certain antitrust-related terminations, the purchaser must pay AdaptHealth a $9.4 million fee. Following closing, the Diabetes Health business will be reported as discontinued operations. Management describes the divestiture as a significant step in a multi-year plan to focus on core Sleep Health, Respiratory Health and Wellness at Home segments, redeploy capital toward these areas, and further strengthen the balance sheet, with more detail to be provided on the August 4, 2026 earnings call.
AdaptHealth Corp. announced that its subsidiary AdaptHealth LLC plans to redeem all outstanding 6.125% Senior Notes due 2028 with an aggregate principal amount of $325,000,000. The notes are expected to be redeemed at 100% of principal plus accrued and unpaid interest up to, but not including, the redemption date.
The redemption is conditioned on receiving sufficient net proceeds from a borrowing under the Issuer’s existing delayed draw term loan facility. The redemption date is expected to be August 1, 2026, with payment of the redemption price expected on the next business day, August 3, 2026, after which interest will no longer accrue on the notes.
AdaptHealth Corp. reports a material cybersecurity incident involving patient data. A threat actor gained unauthorized access to certain cloud-based business applications, including internal patient management systems and document storage platforms, via a social engineering attack on a third-party contractor’s user session.
The company confirmed exfiltration of a stored password file tied to insurance billing and access to external electronic health record portals, affecting passwords and some patients’ personally identifiable and protected health information. The affected systems do not contain Social Security numbers or individual financial account or payment card data.
AdaptHealth has disabled the compromised account, reset credentials, added access controls, engaged external cybersecurity experts and notified law enforcement. As of this report, operations and patient services have not been materially impacted, though the full scope of data involved and the financial impact remain under investigation. The company notes that cybersecurity insurance may cover certain losses.
AdaptHealth Corp. reported the results of its annual stockholder meeting held via live audio webcast. A quorum was present, with 120,652,493 common shares represented, accounting for 88.67% of the voting power entitled to vote.
Stockholders elected nine directors to one-year terms, with each nominee receiving strong majority support. They also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, stockholders approved, on a non-binding advisory basis, the compensation paid to the company’s named executive officers.
AdaptHealth Corp. filed an amended report to correct the Date of Report for its earlier disclosure about appointing Daniel McFadden as Chief Operating Officer and to add his final compensation terms. The board’s compensation committee raised his annual base salary from $410,000 to $550,000, retroactive to the May 4, 2026 appointment date, and kept his target annual bonus at 100% of base salary, pro-rated for 2026. He also received a one-time restricted stock unit grant valued at $464,110, with half vesting annually over three years and half vesting between 0% and 200% based on relative total shareholder return over a three-year performance period beginning on February 1, 2026.
AdaptHealth Corp. reported first quarter 2026 results with net revenue of $819.8 million, up 5.4% from $777.9 million a year earlier, and organic revenue growth of 9.1% across all segments. Net loss attributable to AdaptHealth widened to $16.0 million, and Adjusted EBITDA declined to $121.2 million from $127.9 million.
Free cash flow was negative $27.5 million, compared with essentially breakeven a year ago, as the company increased investment in equipment and acquisitions. Management highlighted completing a major de novo expansion tied to a new strategic partner and growing digital patient engagement to 412,000 registered myApp users.
AdaptHealth raised its 2026 net revenue outlook to a range of $3.45 billion to $3.52 billion while maintaining Adjusted EBITDA and free cash flow guidance. Separately, the company terminated Chief Operating Officer Toby Scott Barnhart and appointed Daniel McFadden, previously Chief Business Systems Officer, as the new COO.
AdaptHealth Corp. entered into a new senior secured credit facility totaling $1.1 billion, replacing its prior credit arrangements and extending its debt maturity profile. The package includes a $325 million Term Loan A, a $325 million delayed draw term loan, and a $450 million revolving credit facility.
Proceeds from the new term loan repaid the existing term loan and prior credit agreement, while the delayed draw facility is intended to redeem the 6.125% Senior Notes due 2028, lowering interest expense. The facility, maturing in April 2031, features lower SOFR-based pricing tied to leverage covenants and is supported by recent credit rating upgrades. The company states the transaction does not change its full-year 2026 guidance.
AdaptHealth Corp. reported essentially flat 2025 sales but a swing to loss and outlined higher 2026 targets. Net revenue for 2025 was $3,244.9 million, down 0.5%, while net loss attributable to AdaptHealth was $70.8 million versus prior-year net income of $90.4 million, driven in part by a $128.0 million non-cash goodwill impairment in the Diabetes Health unit. Adjusted EBITDA fell 10.5% to $616.7 million, and fourth quarter Adjusted EBITDA declined 18.7% to $163.1 million, including a $14.5 million legal settlement expense and over $10 million of strategic investments. Cash flow from operations remained strong at $601.8 million, up from $541.8 million, with full-year free cash flow of $219.4 million. The company reduced debt by $250 million in 2025 and received credit upgrades from S&P and Moody’s. For 2026, AdaptHealth guides to net revenue of $3.44–$3.51 billion, Adjusted EBITDA of $680–$730 million, and free cash flow of $175–$225 million, reflecting expectations for improved profitability after a transition year.
AdaptHealth Corp. furnished an update on its recent performance by issuing a press release with financial results for the quarter ended September 30, 2025. The company released these results on November 4, 2025 and attached the full press release as an exhibit to this report.
The disclosure is provided under the results of operations and financial condition section and is treated as “furnished” rather than “filed,” which limits certain legal liabilities. The press release is identified as Exhibit 99.1, with an additional exhibit covering the interactive data for the cover page.